Selecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference

Jul 6, 2022

WATERTOWN, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will participate virtually in a fireside chat and in one-on-one investor meetings at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference, to be held virtually and in-person in New York, NY July 12-13.

Guggenheim I&I Spotlight Series – Treg-based Therapies Conference
Format: Fireside chat and one-on-one investor meetings
Date: Wednesday, July 13, 2022
Time: 1:00 p.m. ET
Webcast: Click Here

An archived webcast will also be accessible in the Investors & Media section of the company’s website at

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit

For Investors:
Bruce Mackle
LifeSci Advisors, LLC

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC


Primary Logo

Source: Selecta Biosciences, Inc.